M&A / Deals GSK bolts on siRNA drug from China’s SiranBio in $1bn deal PharmaphorumGSK has extended its pipeline of siRNA drugs once again by licensing an ALK7-targeted therapy for cardiometabolic diseases from SiranBio.Read full story pharminent May 6, 2026 (Last updated: May 6, 2026) Pharmaphorum GSK has extended its pipeline of siRNA drugs once again by licensing an ALK7-targeted therapy for cardiometabolic diseases from SiranBio. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: CellCentric raises $220M for a ‘transformative’ multiple myeloma medicineNext: CellCentric secures $220M in Europe’s biggest private biotech fundraise of 2026 Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
